Long-lasting complete response of metastatic melanoma to ipilimumab with analysis of the resident immune cells (Q38171355)

30 August 2017

title

Long-lasting complete response of metastatic melanoma to ipilimumab with analysis of the resident immune cells (English)

1 reference

30 August 2017

0 references

1 reference

7

Giuliano Ramadori

1 reference

30 August 2017

Birgit Tsaknakis

1

1 reference

30 August 2017

Inga-Marie Schaefer

2

1 reference

30 August 2017

Harald Schwörer

3

1 reference

30 August 2017

Carsten-Oliver Sahlmann

4

1 reference

30 August 2017

Kai-Martin Thoms

5

1 reference

30 August 2017

Martina Blaschke

6

1 reference

30 August 2017

Silke Cameron

8

1 reference

30 August 2017

publication date

14 December 2013

1 reference

30 August 2017

1 reference

30 August 2017

volume

31

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

813

1 reference

Epidemiology of cutaneous melanoma in Germany and worldwide

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Targeting the RAS pathway in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Adjuvant therapy: melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Cytokine therapy in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Structure and expression of a cloned cDNA for human interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Cytokine-based therapy and biochemotherapy for advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Treatment with ipilimumab: a case report of complete response in a metastatic malignant melanoma patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Immunotherapy for advanced melanoma: fulfilling the promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Contemporary Diagnostic Imaging Modalities for the Staging and Surveillance of Melanoma Patients: a Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Do we need a different set of response assessment criteria for tumor immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Checkpoint blockade in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

The chemokine system in diverse forms of macrophage activation and polarization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0813-3

Treatment and side effect management of CTLA‐4 antibody therapy in metastatic melanoma

21 January 2018

1 reference

12 December 2020

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system

1 reference

12 December 2020

A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma

1 reference

12 December 2020

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

12 December 2020

[S3-Guidelines "Exocrine pancreatic cancer" 2007]

1 reference

12 December 2020

Use of ipilimumab in the treatment of melanoma

1 reference

12 December 2020

A role for hepatic metastasectomy in stage IV melanoma and breast cancer: reestablishing the surgical modality.

1 reference

12 December 2020

Infiltration of tumours by macrophages and dendritic cells: tumour-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes

1 reference

12 December 2020

10.1007/S12032-013-0813-3

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

1026777086

0 references

1 reference